Compare Abeona Therapeutics Inc (ABEO) vs JD.Com Inc (JD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs JD.Com Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while JD.Com Inc trades at $27.62 (market cap $36.37B). The key difference: JD.Com Inc is far larger — about 97.4× Abeona Therapeutics Inc's market cap, and JD.Com Inc pays a 3.78% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | JD | |
|---|---|---|
Market Cap | $373.32M | $36.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $36.17 |
52-Week Low | $4.17 | $25.19 |
Enterprise Value | $228.22M | $22.53B |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JD trades at $26.49, down 0.49% on the day, with a bearish technical signal and mixed sentiment. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 show operational strength, but net income margin compression to 1.05% in 2025 raises concerns. The stock appears undervalued with a P/S of 0.2 and P/E of 19.66, while analyst consensus remains strongly bullish with a $39.20 price target.
The outlook is cautiously optimistic given JD's low valuation and consistent earnings outperformance, but risks include legal investigations, margin pressure, and macroeconomic headwinds. Upside potential exists if the company can sustain revenue growth and improve profitability, though near-term volatility may persist due to negative news flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
